Plot twist in biotech: GSK just ditched its five-year cancer partnership with Ideaya, leaving the smaller company to figure out what to do with two of its promising cancer drug programs. No word on why GSK bailed, but Ideaya says they’re still good on cash till 2030 and are weighing new partners or going solo. The real drama? Whether these treatments can still make it big without GSK’s muscle. #Health #BodyHealth #biotech